オハイオにおける乾癬の臨床試験
オハイオ内の拠点で、乾癬に関する9件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
- LEO Pharma Investigation Site, Mayfield Heights
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07013201Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中
18歳〜94歳 · 全性別 · 2026/09/04更新 · NCT06399432A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Optima Research - Boardman, Boardman
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06857942A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Apex Clinical Research Center - Canton, Canton
- Apex Clinical Research Center, Lorain
- Apex Clinical Research Center, Mayfield Heights
被験者募集中第3相
12歳〜17歳 · 全性別 · 2026/09/03更新 · NCT06979453A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
- Ppp001 50745, Columbus
- Ppp001 50202, Fairborn
- Ppp001 50733, Mayfield Heights
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07219420A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
- Study Center, Mayfield Heights
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/07/09更新 · NCT07489885Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第4相
18歳〜89歳 · 全性別 · 2026/04/02更新 · NCT05270733IMPACT - AndHealth Autoimmune Research Registry
- AndHealth, Columbus
被験者募集中観察研究
18歳〜70歳 · 全性別 · 2023/06/29更新 · NCT05883371ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。